Autoantibodies in Post-Acute COVID Vaccination Syndrome
Author Information
Author(s): Mauro Mantovani, Paolo Bellavite, Serafino Fazio, Giuseppe Di Fede, Marco Tomasi, Daniele Belli, Elisabetta Zanolin, Toshihiro Kita
Primary Institution: Istituto di Medicina Biologica, Milan, Italy
Hypothesis
The study investigates the presence of autoantibodies targeting G-protein-coupled receptors and RAS-related molecules in patients with post-acute COVID vaccination syndrome (PACVS).
Conclusion
The study suggests that autoantibodies against ACE2, MAS1, and STAB1 may serve as biomarkers for PACVS.
Supporting Evidence
- Patients reported a variety of symptoms including chronic fatigue, memory loss, and skin issues.
- High levels of autoantibodies were found in patients with PACVS.
- Statistical analysis showed significant associations between certain autoantibodies and symptoms.
Takeaway
Some people may feel sick after getting a COVID vaccine, and this study found that certain antibodies in their blood could help explain why.
Methodology
This was a single-center retrospective study analyzing medical records of 17 vaccinated patients who developed symptoms compatible with PACVS.
Potential Biases
The observational nature of the study may introduce selection bias.
Limitations
The study is limited by its small sample size and lack of a control group.
Participant Demographics
The cohort consisted of 13 women and 4 men with a mean age of 44 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website